Alamar Biosciences secures $128M, led by Sands Capital, for their precision proteomics platform. Series C funding, totaling nearly $250M, will enhance early disease detection with NULISA technology, offering unmatched sensitivity and precision. The investment will drive commercial expansion, market adoption, and portfolio diversification, positioning Alamar to revolutionize disease diagnosis and biomarker discovery. CEO Dr. Yuling Luo expresses gratitude and confidence in the company’s future.
Alamar Biosciences Secures $128M Investment to Advance Proteomics Platform: Key Points to Note
– Alamar Biosciences, a frontrunner in precision proteomics for early disease detection, has raised $100M in its Series C funding round, with an additional $28M anticipated within the next 30 days. This latest infusion brings their total funding to nearly $250M.
– The Series C funding was spearheaded by Sands Capital, with participation from a mix of new and existing investors, encompassing both financial and strategic partners. Ian Ratcliffe, Executive Managing Partner at Sands Capital, has assumed a seat on Alamar’s Board of Directors.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Revolutionizing Early Disease Detection
Alamar’s groundbreaking NULISA technology empowers researchers and clinicians with:
– Unparalleled Sensitivity: NULISA employs an innovative capture and release mechanism, boasting a 10,000-fold enhancement in signal-to-noise ratio compared to conventional methods. This enables the detection of proteins at remarkably low concentrations (in single digit attomolar range).
– Enhanced Precision: Complemented by qPCR and NGS readouts, NULISA facilitates targeted analysis of specific biomarkers as well as large-scale profiling of hundreds to thousands of proteins, providing a comprehensive understanding of disease states.
– Improved Efficiency: The recently launched ARGO HT System automates NULISA assays, demanding less than 30 minutes of hands-on time.
Funding Fuels Growth and Innovation
Alamar intends to leverage the funds to:
– Expand its commercial and customer support teams: Ensuring broad adoption and seamless integration of their technology.
– Stimulate market adoption: Actively engaging with healthcare professionals and researchers to harness the potential of NULISA for early disease detection.
– Broaden the product portfolio: Offering a diverse array of tools and solutions tailored to specific disease areas.
Dr. Yuling Luo, Founder, Chairman & CEO of Alamar, expressed gratitude for the robust support received from the investor consortium. She highlighted the company’s transformative technology, robust intellectual property, and strong initial market uptake. Dr. Luo emphasized that the proprietary NULISA™ technology’s exceptional performance and unique capabilities will enable customers to expedite biomarker discovery and develop non-invasive tests for diseases with significant unmet needs. With this funding, Alamar is poised to spearhead precision proteomics through accelerated commercialization.
